Table 3.
Hyperglycemia | Arm A:IMC-A12 (n = 23) |
Arm B: IMC-A12 + Cetuximab (n = 21) |
Arm C: IMC-A12 + Cetuximab and KRAS Wild Type (n = 20) |
Total |
||||
---|---|---|---|---|---|---|---|---|
No. | % | No. | % | No. | % | No. | % | |
Grade 1 | 0 | 0 | 0 | 0 | ||||
Grade 2 | 0 | 1 | 5 | 1 | 5 | 2 | 3 | |
Grade 3 | 1 | 4 | 0 | 0 | 1 | 2 | ||
Grade 4 | 0 | 0 | 0 | 0 | ||||
Grade 5 | 0 | 0 | 0 | 0 |